key: cord-0795127-o1bdqyeh authors: Duan, Zhen; Liu, Mandie; Yuan, Lin; Du, Xizi; Wu, Mengping; Yang, Yu; Wang, Leyuan; Zhou, Kai; Yang, Ming; Zou, Yizhou; Xiang, Yang; Qu, Xiangping; Liu, Huijun; Qin, Xiaoqun; Liu, Chi title: Innate lymphoid cells are double‐edged swords under the mucosal barrier date: 2021-08-10 journal: J Cell Mol Med DOI: 10.1111/jcmm.16856 sha: 0ea6f9598f8c42444aabb06f39206a146daf793d doc_id: 795127 cord_uid: o1bdqyeh As the direct contacting site for pathogens and allergens, the mucosal barrier plays a vital role in the lungs and intestines. Innate lymphoid cells (ILCs) are particularly resident in the mucosal barrier and participate in several pathophysiological processes, such as maintaining or disrupting barrier integrity, preventing various pathogenic invasions. In the pulmonary mucosae, ILCs sometimes aggravate inflammation and mucus hypersecretion but restore airway epithelial integrity and maintain lung tissue homeostasis at other times. In the intestinal mucosae, ILCs can increase epithelial permeability, leading to severe intestinal inflammation on the one hand, and assist mucosal barrier in resisting bacterial invasion on the other hand. In this review, we will illustrate the positive and negative roles of ILCs in mucosal barrier immunity. damaged mucosal-derived 'risk signals' sensitively and quickly due to the close proximity of the damaged site, triggering ILC-mediated subsequent inflammatory response and tissue repair. Significant attention is paid to the role of ILCs that may also be of great therapeutic potential in mucosal diseases. In this review, we focus on the physiological and pathological functions of ILCs in the mucosal barrier. Meanwhile, we summarize the positive and negative roles of ILCs in mucosal barrier immunity. When external irritations stimulate mucosae, ILCs play a positive role to maintain mucosal homeostasis by alleviating inflammation and promoting tissue repair. However, excessive ILCs can also play a negative role by recruiting inflammatory cells and pro-inflammatory cytokines, leading to damage the integrity of mucosae and accelerate the pathological process of chronic mucosal diseases. The mucosal barrier is the first site to contact with the environmental antigens and pathogens, such as viruses, fungi, parasites and bacteria. The intact epithelia, cilia and mucus together constitute a strong physical barrier against external stimulus. A variety of allergens and stimuli, except probiotics, are detrimental to the host. After prolonged and/or extensive exposure to ozone, house dust mite (HDM), bacteria and viruses, etc., epithelial structural proteins such as E-cadherin and zonula occludens-1 (ZO-1) were destructed, resulting in decreased epithelial tightness and barrier damage. [1] [2] [3] [4] The dysfunction of epithelia is a common pathological characteristic of mucosal diseases. Various degrees of epithelial damage are the key determinant of mucosal diseases such as asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel diseases (IBD) and the degree of epithelial damage is positively correlated with the severity of diseases. [5] [6] [7] Once the mucosal system is too vulnerable to identify and/or eliminate noxious stimuli in time, pathogen-induced inflammation may damage the mucosal barrier excessively, leading to severe infection, cytokine storm or even death eventually. [8] [9] [10] [11] The mucosal system can be involved in many mucosal diseases in addition to its physical barrier function. More importantly, it also has a powerful immune function. When the structure and function of the mucosal barrier are damaged, mucosal epithelia would secret cytokines and inflammatory mediators to trigger systemic immune response and eliminate pathogens, which in turn restore the homeostasis of the mucosal barrier. 12, 13 In the process of mucosal immune response, ILCs have attracted a substantial amount of attention due to special distribution and function. A large number of studies have demonstrated that the activation and differentiation of ILCs have great biological significance in regulating local inflammation and promoting tissue repair in the mucosal barrier. The distribution and function of ILCs in the mucosal barrier and the involvement of ILCs in mucosal diseases deserve further study. In recent years, ILCs have aroused broad attention in the mucosal immunity and the homeostasis of mucosal barrier. ILCs are renewed from progenitors, and recent studies have identified that CD117 + ILC precursors derived from CD34 + hematopoietic stem cells can generate almost all mature ILC subsets (except for interleukin-17A + ILC3s) under appropriate environmental signals. 14, 15 Interestingly, CD117 + ILC precursors can circulate in the peripheral blood or reside in the tissues, but lineage-specified progenitors of ILC3s can be detected in tonsil and intestinal lamina propria but not in peripheral blood. 16 Of note, ILCs are sentinel cells distributed widely in the mucosal barrier, while most mature ILCs are resident in intestine lamina propria, lung and liver. 17 As ILCs are similar to T cells in terms of transcription and function, there are ILC subsets such as ILC1, ILC2, ILC3 and ILCreg by reference to the subsets of T cells (Table 1) . [18] [19] [20] ILCs are developed and expanded within peripheral organs, and then acute infections or tissue damage rapidly triggers ILC precursors to differentiate into mature ILCs following cytokine-driven expansion. 21, 22 ILCs do not express antigen-specific receptors, and cytokines are considered as powerful activators of ILCs. ILCs can directly respond to epithelial cytokines in the absence of T cells and even respond to 'risk signal' faster than T cells. [23] [24] [25] Furthermore, ILC2s activated by IL-33 may produce 10 times more type 2 cytokines than Th2 cells do. 26 ILCs are involved in the first-line immune defence by secret- NK cells. 27 Besides, IL-25 can induce ILC2s to produce IL-5 and IL-13 even in RAG-deficient mice. 28 Intriguingly, there are a series of IL-10-secreting ILCs, generated in severe inflammatory environment, which in turn alleviate inflammation in different ways. [29] [30] [31] It is revealed that the interaction between inflammatory factors and IL-10-secreting ILCs may initiate tissue damage repair, which may constitute a negative feedback system to guard the mucosal immune system and the homeostasis of mucosae. The interaction between cytokines and ILCs is intricate and complex. The differentiation and function of ILCs can also be regulated by cytokines in local microenvironment. [32] [33] [34] In the complex mucosal environment, ILCs are heterogeneous and highly plastic. To sum up, ILCs are abundant in mucosal barrier, close to the damaged site, and can respond to inflammatory signal sensitively. Particularly, ILCs are of typical plasticity, which indicates that ILCs may function as a double-edged sword in mucosal barrier. The various characteristics of ILCs indicate that they have great potential in mucosal diseases. We will elucidate how ILCs regulate the immune responses and maintain the homeostasis of mucosal barriers involving lungs and intestines. As a tissue directly contacting the external environment, lung mucosae need to cope with airborne dust, pollen, ozone, microbes, etc. Submucosal ILCs are essential for the integrity and homeostasis of the lung mucosal barrier. Upon sensing the 'risk signal' from damaged mucosal epithelia, ILCs will proliferate, activate and release various cytokines to respond to harmful environmental components promptly and appropriately. Non-recirculating ILCs in the lungs con- 50 Furthermore, given that IL-17A is a detrimental factor to COPD, IL-17-secreting ILC3s may also participate in the pathology of COPD. 51 The exacerbation of COPD is associated with ILC1s, while the lung functionality of asthma patients is closely related to ILC2s. 52 The frequency of ILC2s is increased in allergic asthma patients, which are sufficient to initiate asthma. 53 70 In addition, IL-17producing ILC3s promote AHR in obesity-associated asthma. 71, 72 Except for COPD and asthma, several studies have revealed that ILC2s are involved in the pathogenesis of chronic rhinosinusitis with nasal polyps and idiopathic pulmonary fibrosis. 73, 74 There is no doubt ILC-regulated mucosal immunity is of great significance to lung defence and chronic diseases. A proper ILCmediated defence is very beneficial to the homeostasis of lung. However, when lung mucosae are severely damaged or in a state of long-term damage, ILCs will lead to the development of chronic pulmonary diseases. Notably, different subtypes of ILCs have different effects on the outcome of lung disease. How ILCs function in different environments and the role of ILCs plasticity in chronic diseases still need further study. Particularly, the investigation about the activation and function of ILC3s in lung mucosae is relatively rare. Besides, infections with extracellular bacteria and fungi are lack of concern in ILC-regulated lung immunity. In-depth studies on resident ILCs in the lungs are expected to provide new perspective to the treatment of these pulmonary diseases. The intestines must process a large amount of food every day and I would like to express my gratitude to all those who helped me during the writing of this review, and I deeply appreciate the contribution to this review made by them. The authors declare no conflict of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. https://orcid.org/0000-0003-2872-9576 Epithelial cell-intrinsic Notch signaling plays an essential role in the maintenance of gut immune homeostasis Ozone-induced bronchial epithelial cytokine expression differs between healthy and asthmatic subjects E-cadherin as an epithelial barrier protein in exhaled breath condensate Defective epithelial barrier function in asthma Airway epithelial cell differentiation relies on deficient Hedgehog signalling in COPD Role of airway epithelial barrier dysfunction in pathogenesis of asthma Colonic epithelial cell diversity in health and inflammatory bowel disease Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients SIDS Sudden Infant and Early Childhood Death: The Past, the Present and the Future Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells Epithelial-Derived Cytokines in Asthma Epithelial cell-derived cytokines: more than just signaling the alarm Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation ILC-poiesis: Making Tissue ILCs from Blood Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs Innate lymphoid cells: parallel checkpoints and coordinate interactions with T cells Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update) Human innate lymphoid cells ILC-poiesis: Ensuring tissue ILC differentiation at the right place and time ILC-poiesis': generating tissue ILCs from naive precursors Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites Innate Lymphoid Cells (ILCs): Cytokine Hubs Regulating Immunity and Tissue Homeostasis The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction IL-33, IL-25 and TSLP contribute to development of fungal-associated protease-induced innate-type airway inflammation TH2, allergy and group 2 innate lymphoid cells Alternative activation generates IL-10 producing type 2 innate lymphoid cells Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid Regulatory innate lymphoid cells control innate intestinal inflammation Chemokine regulation of innate lymphoid cell tissue distribution and function Complexity of cytokine network regulation of innate lymphoid cells in protective immunity Cytokine Networks between Innate Lymphoid Cells and Myeloid Cells Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity Imbalance of NKp44(+) NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues Interleukin-12 and -23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria Dysregulation of group 3 innate lymphoid cells in the pathogenesis of inflammatory bowel disease Influenza-activated ILC1s contribute to antiviral immunity partially influenced by differential GITR expression Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection IL-22 is essential for lung epithelial repair following influenza infection IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminthinduced lung inflammation Innate lymphoid cells: critical regulators of allergic inflammation and tissue repair in the lung Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs IL-17 in lung disease: friend or foe? Innate lymphoid cells of the lung Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9(+) and IL-13(+) type 2 innate lymphoid cell subpopulations Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity Enhanced innate type 2 immune response in peripheral blood from patients with asthma Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma IL-13(+) Type 2 Innate Lymphoid Cells Correlate with Asthma Control Status and Treatment Response IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and gammadelta T cells Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia Type 2 innate lymphoid cells in induced sputum from children with severe asthma Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: The role of thymic stromal lymphopoietin Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation Tezepelumab in Adults with Uncontrolled Asthma Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells Respiratory syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic stromal lymphopoietin Pulmonary epithelial cellderived cytokine TGF-beta1 Is a critical cofactor for enhanced innate lymphoid cell function Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesityassociated airway hyperreactivity Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease ILC3 function as a double-edged sword in inflammatory bowel diseases Commensal and Pathogenic Bacteria Indirectly Induce IL-22 but Not IFNgamma Production From Human Colonic ILC3s via Multiple Mechanisms CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22 Enteric bacteria induce IFNgamma and Granzyme B from human colonic Group 1 Innate Lymphoid Cells Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration A Metabolite-Triggered Tuft Cell-ILC2 Circuit Drives Small Intestinal Remodeling Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria Role of the intestinal mucosa in acute gastrointestinal GVHD Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism IL22 Inhibits epithelial stem cell expansion in an ileal organoid model Interleukin 22 Expands Transit-Amplifying Cells While Depleting Lgr5(+) Stem Cells via Inhibition of Wnt and Notch Signaling Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice IL-17 and IL-22 in immunity: Driving protection and pathology Brief Report: Inflammatory Colonic Innate Lymphoid Cells Are Increased During Untreated HIV-1 Infection and Associated With Markers of Gut Dysbiosis and Mucosal Immune Activation MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production Type 2 innate lymphoid cells drive CD4+ Th2 cell responses Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis Innate lymphoid cells are double-edged swords under the mucosal barrier